TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

THE GOOD
Approvals & Labels

Pierre Fabre’s Obgemsa (viberon) passes the EMA vibe check, approved
Small molecule, overactive bladder (OAB) syndrome - Read more

Idorsia also lands EMA approval for resistant hypertension
Small molecule, resistant hypertension - Read more

Samsung Bioepis’ Stelara (J&J) biosimilar handed FDA approval
Monoclonal antibody, biosimilar, severe plaque psoriasis - Read more

THE GOOD
Business Development

Eli Lilly signs another radiopharma deal, this time with Radionetics
Radionetics to receive $140M, Eli Lilly gets option to acquire Radionetics for $1B after “exercise period”
Radiopharmaceuticals, cancer - Read more

Tonix Pharmaceuticals lands up to $34M US DOD contract
Small molecule, broad-spectrum antiviral, Defense Threat Reduction Agency - Read more

Esperion Therapeutics signs away cholesterol med royalties to OMERS Life Sciences for approximately $304.7M
Small molecule, cholesterol, hypercholesterolemia - Read more

uniQure sells gene therapy manufacturing site to Genezen
uniQure to receive $25M (stock & debt)
Gene therapy, manufacturing hemophilia B - Read more

THE GOOD
Clinical Trials

Boehringer Ingelheim, Gubra begin Ph1 for novel “first-in-class” obesity treatment
Peptide, triple agonist, obesity - Read more

Dianthus Therapeutics releases pre-clinical data in support of Ph2 asset
Monoclonal antibody, myasthenia gravis (gMG), chronic demyelinating polyneuropathy (CIDP) - Read more

Ovid Therapeutics, Graviton Biosciences present Ph1 safety data
Small molecule, cerebral cavernous malformations - Read more

Lone patient in ultra-rare disease Ph1 makes positive progress, potential roadmap for individualized rare disease treatments
AAV gene therapy, spastic paraplegia type 50 (SPG50) - Read more

THE GOOD
Fundraises

Freeflow Ventures $90M Fund close
Human health challenges, early-stage venture capital - Read more

Kanvas Biosciences $12.5M Fundraise
Spatial biology, microbiome-based therapeutic - Read more

N-Power Series B (undisclosed amount)
Clinical trials network, clinical trial recruitment - Read more

THE GOOD
Investments

Veranova invests $30M into ADC manufacturing facility
CDMO, antibody-drug conjugates, API - Read more

Partners Group buys majority stake in FairJourney Biologics
CRO, antibody research - Read more

THE GOOD
IPOs

Artiva Biotherapeutics rides cell therapy autoimmune wave to an IPO (this time for real?)
NK cell therapy, allogeneic, autoimmune - Read more 

THE GOOD
Lawsuits

GSK settles another Zantac suit
Small molecule, heartburn, cancer - Read more

THE GOOD
Partnerships

Merck & Co. and Orion tacks licensing agreement onto existing drug discovery partnership
Orion to potentially receive: $30M R&D milestones, $625M regulatory milestones, $975M sales milestones
Small molecule, cancer - Read more

THE GOOD
Patient Access

Huzzah! FDA announces cisplatin no-longer in short supply
Drug shortage, small molecule, chemotherapy, cancer - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

TRACON Pharmaceuticals drop sarcoma asset after Ph2 miss
Monoclonal antibody, sarcoma, cancer - Read more

THE BAD
Layoffs

Aerovate Therapeutics cuts “nearly all” staff after Ph2b failure
Small molecule, pulmonary arterial hypertension - Read more

Takeda continues shedding staff in MA, 220 employees - Read more [Paywall]

Dexcom lays off a whopping 535 staffers in San Diego
Medical device, diabetes sensor - Read more

Ovid Therapeutics cuts 17 employees (43% of staff)
Small molecule, epilepsy, neurological disorder - Read more

THE BAD
Partnership

Bristol Myers Squibb ends $650M ADC strategic partnership with Eisai
Antibody-drug conjugate, solid tumors, cancer - Read more

THE BAD
Patient Access

Walgreens’ plan to shutter “significant portion” of stores could exacerbate pharmacy access issues in underprivileged communities - Read more

THE BAD
Regulatory

FDA needs to be more transparent about CRLs after recent spate of third-party manufacturer-related rejections; opinion
Outsourced manufacturing, complete response letter - Read more

THE UGLY
Criminal Acts

The Cassava Sciences drama continues, internal investigation squared on two senior employees
Small molecule, Alzheimer’s, research fraud - Read more

THE UGLY
Lawsuits

J&J talc subsidiary bankruptcy plan marches on despite plaintiffs attempted restraining order
Talc powder, ovarian cancer - Read more 

THE UGLY
Politics & Policy

FTC comes out swinging, goes after multiple “bogus” Teva Pharmaceutical patents
Drug patents, Orange Book, biosimilar - Read more [Paywall]

THE UGLY
Withdrawals & Recalls

FDA doesn’t hold back on ventilator recalls, Class 1’s for Baxter, Philips, Zoll
Medical device, ventilator, sleep apnea - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 450+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.